ClinicalTrials.gg
CompletedNCT01662648Updated May 5, 2014Results posted

Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia

A Phase 3 interventional study of Paliperidone ER in Schizophrenia, sponsored by Janssen Pharmaceutica. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-05.

Sponsored by Janssen Pharmaceutica (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,117
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
4th of 115
1,117 · median 178
Started
2007
with 14 others
Phase 3
41 of 115
none open now
Registered
80th of 115
by date
Lead sponsor
2 of 115
Janssen Pharmaceutica

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 4th largest by enrollment, is one of 15 that started in 2007, is one of 41 in phase 3, and was the 80th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to explore the efficacy of flexibly dosed paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) who were previously unsuccessfully treated with other oral antipsychotics.

Read the detailed description

This is a single arm (one group of participants), multi-center, 6-month study to explore the tolerability, safety and efficacy of flexibly dosed paliperidone ER in participants with schizophrenia previously unsuccessfully treated with an oral antipsychotic medication. Antipsychotic medications are drugs that are helpful in the treatment of psychosis and have a capacity to ameliorate thought disorders. Unsuccessfully treated means that, despite the participant was treated with an adequate dose of an appropriate oral antipsychotic for an adequate period of time, previous treatment is considered unsuccessful due to lack of efficacy, lack of tolerability or safety, lack of compliance and/or other reasons. Throughout the study the investigators will adjust the dosage of each participant based on the individual needs. In general, the recommended paliperidone ER dose will be 6 milligram once daily. Participants can be either in- or outpatients and they may take their study drug with or without food. Participants who will complete this 6-month study and would like to continue will be eligible to be enrolled in an extension phase until paliperidone ER is available.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Paliperidone
  • Paliperidone extended-release (ER)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant diagnosed with schizophrenia
  • Participant's previous treatment of schizophrenia is considered unsuccessful
  • Participant is healthy on the basis of a physical examination and vital signs
  • Women must be , surgically sterile, abstinent, or, if sexually active, agree to practice an effective method of before entry and throughout the study
  • Be willing and able to fill out self-administered questionnaires

Exclusion criteria

Exclusion Criteria:

  • Have used clozapine or Risperdal CONSTA during the last month, or have received any other conventional drug used to treat psychosis during the last 3 months
  • Judged to be at high risk for adverse events, violence or self-harm
  • Inability to swallow the study medication whole with the aid of water
  • Pregnant or breast-feeding female
  • History or current symptoms of tardive dyskinesia (involuntary movements of the facial muscles and tongue)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,117 participants (actual)

Study arms

  • Experimental
    Paliperidone ER: Lack of efficacy

    Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics for the main reason of lack of efficacy.

    Drug: Paliperidone ER

  • Experimental
    Paliperidone ER: Lack of tolerability, compliance or other

    Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics for the main reason of lack of tolerability, compliance or other reasons.

    Drug: Paliperidone ER

Interventions

  • Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

    Time frame: Baseline and Week 26

Secondary outcomes

  1. Percentage of Participants With Greater Than or Equal to 20 Percent (%) Improvement in PANSS Total Score at Week 26

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. Percentage of participants with greater than or equal to 20 % improvement in PANSS total score is reported here. Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

    Time frame: Week 26

  2. Change From Baseline in PANSS Total Positive Subscale Score at Week 26

    The Positive Subscale of PANSS (Positive and Negative Syndrome Scale) assesses seven positive-symptoms of schizophrenia. Positive symptoms refer to an excess of or distortion of normal functions. The symptoms are rated on a 7-point scale, ranging from 7 (absent) to 49 (extreme psychopathology). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

    Time frame: Baseline and Week 26

  3. Change From Baseline in PANSS Total Negative Subscale Score at Week 26

    The Negative Subscale of PANSS (Positive and Negative Syndrome Scale) assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, ranging from 7 (absent) to 49 (extreme psychopathology). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

    Time frame: Baseline and Week 26

  4. Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Week 26

    The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 indicates to "normal, not at all ill" and a rating of 7 indicates "among the most extremely ill participants". Higher scores indicate worsening. Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

    Time frame: Baseline and Week 26

  5. Change From Baseline in Personal and Social Performance (PSP) Scale at Week 26

    The PSP scale assesses the degree of dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Participants with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; less or equal to 30, functioning so poorly as to require intensive supervision. Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

    Time frame: Baseline and Week 26

  6. Change From Baseline in Sleep Quality at Week 26

    Sleep quality was assessed by an 11-point visual analog scale that rates how well participants sleep. Participants indicated on the scale (from 0 to 100 millimeter) how well they have slept in the previous 7 days (from 0: "very badly" to 100: "very well"). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

    Time frame: Baseline and Week 26

  7. Change From Baseline in Daytime Drowsiness at Week 26

    Daytime Drowsiness was assessed by an 11-point visual analog scale that rates how well participants sleep. Participants indicated on the scale (from 0 to 100 millimeter) how often they have felt drowsy within the previous 7 days (from 0: "not at all" to 100:"all the time"). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

    Time frame: Baseline and Week 26

  8. Number of Participants Within Each Category of Patient Satisfaction Score

    Participants were interviewed at baseline and at the end of the trial (Week 26) to assess their satisfaction with the current treatment on a 5-point scale (very good, good, reasonable, moderate or poor). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

    Time frame: Baseline and Week 26

07

Results

Posted Mar 26, 2014

Participant flow

Participant flow — Overall Study
MilestonePaliperidone ER: Lack of EfficacyPaliperidone ER: Lack of Tolerability, Compliance or Other
Started520597
Completed373419
Not completed147178
Withdrew: Death13
Withdrew: Adverse event4037
Withdrew: Lack of efficacy1716
Withdrew: Participant ineligible to continue trial11
Withdrew: Lost to follow-up2436
Withdrew: Withdrawal by subject3653
Withdrew: Participant non-compliant1620
Withdrew: Other811
Withdrew: Adverse event and lack of efficacy (loe)30
Withdrew: Loe and other reason unspecified10
Withdrew: Loe and participant non-compliant01

Outcome measures

PrimaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

Time frame:
Baseline and Week 26
Reported as:
Mean · units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26
units on a scalePaliperidone ER: Lack of EfficacyPaliperidone ER: Lack of Tolerability, Compliance or Other
Baseline85.19 ± 24.9765.45 ± 28.48
Week 26-26.60 ± 28.24-20.52 ± 30.05
SecondaryPercentage of Participants With Greater Than or Equal to 20 Percent (%) Improvement in PANSS Total Score at Week 26

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. Percentage of participants with greater than or equal to 20 % improvement in PANSS total score is reported here. Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Greater Than or Equal to 20 Percent (%) Improvement in PANSS Total Score at Week 26
percentage of participantsPaliperidone ER: Lack of EfficacyPaliperidone ER: Lack of Tolerability, Compliance or Other
Percentage of Participants With Greater Than or Equal to 20 Percent (%) Improvement in PANSS Total Score at Week 2672.8371.87
SecondaryChange From Baseline in PANSS Total Positive Subscale Score at Week 26

The Positive Subscale of PANSS (Positive and Negative Syndrome Scale) assesses seven positive-symptoms of schizophrenia. Positive symptoms refer to an excess of or distortion of normal functions. The symptoms are rated on a 7-point scale, ranging from 7 (absent) to 49 (extreme psychopathology). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

Time frame:
Baseline and Week 26
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Total Positive Subscale Score at Week 26
units on a scalePaliperidone ER: Lack of EfficacyPaliperidone ER: Lack of Tolerability, Compliance or Other
Baseline21.04 ± 7.1515.26 ± 7.53
Week 26-7.17 ± 7.67-5.07 ± 7.88
SecondaryChange From Baseline in PANSS Total Negative Subscale Score at Week 26

The Negative Subscale of PANSS (Positive and Negative Syndrome Scale) assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, ranging from 7 (absent) to 49 (extreme psychopathology). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

Time frame:
Baseline and Week 26
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Total Negative Subscale Score at Week 26
units on a scalePaliperidone ER: Lack of EfficacyPaliperidone ER: Lack of Tolerability, Compliance or Other
Baseline22.73 ± 7.8616.90 ± 8.13
Week 26-6.93 ± 7.96-5.32 ± 8.12
SecondaryChange From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Week 26

The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 indicates to "normal, not at all ill" and a rating of 7 indicates "among the most extremely ill participants". Higher scores indicate worsening. Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

Time frame:
Baseline and Week 26
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Week 26
units on a scalePaliperidone ER: Lack of EfficacyPaliperidone ER: Lack of Tolerability, Compliance or Other
Baseline4.24 ± 0.833.29 ± 1.12
Week 26-1.12 ± 1.28-0.98 ± 1.30
SecondaryChange From Baseline in Personal and Social Performance (PSP) Scale at Week 26

The PSP scale assesses the degree of dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Participants with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; less or equal to 30, functioning so poorly as to require intensive supervision. Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

Time frame:
Baseline and Week 26
Reported as:
Mean · units on a scale
Change From Baseline in Personal and Social Performance (PSP) Scale at Week 26
units on a scalePaliperidone ER: Lack of EfficacyPaliperidone ER: Lack of Tolerability, Compliance or Other
Baseline (n= 506, 583)55.07 ± 15.6866.03 ± 15.65
Week 26 (n= 501, 574)13.76 ± 17.8011.14 ± 17.53
SecondaryChange From Baseline in Sleep Quality at Week 26

Sleep quality was assessed by an 11-point visual analog scale that rates how well participants sleep. Participants indicated on the scale (from 0 to 100 millimeter) how well they have slept in the previous 7 days (from 0: "very badly" to 100: "very well"). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

Time frame:
Baseline and Week 26
Reported as:
Mean · millimeter (mm)
Change From Baseline in Sleep Quality at Week 26
millimeter (mm)Paliperidone ER: Lack of EfficacyPaliperidone ER: Lack of Tolerability, Compliance or Other
Baseline (n= 507, 581)63.53 ± 27.3767.40 ± 27.13
Week 26 (n= 504, 574)11.57 ± 35.708.19 ± 35.93
SecondaryChange From Baseline in Daytime Drowsiness at Week 26

Daytime Drowsiness was assessed by an 11-point visual analog scale that rates how well participants sleep. Participants indicated on the scale (from 0 to 100 millimeter) how often they have felt drowsy within the previous 7 days (from 0: "not at all" to 100:"all the time"). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

Time frame:
Baseline and Week 26
Reported as:
Mean · millimeter (mm)
Change From Baseline in Daytime Drowsiness at Week 26
millimeter (mm)Paliperidone ER: Lack of EfficacyPaliperidone ER: Lack of Tolerability, Compliance or Other
Baseline (n= 507, 581 )32.80 ± 27.5634.54 ± 28.61
Week 26 (n= 504, 574)-9.52 ± 32.29-11.54 ± 34.53
SecondaryNumber of Participants Within Each Category of Patient Satisfaction Score

Participants were interviewed at baseline and at the end of the trial (Week 26) to assess their satisfaction with the current treatment on a 5-point scale (very good, good, reasonable, moderate or poor). Data for two groups is presented here, based on the reason to switch: lack of efficacy and lack of tolerability, compliance or other who switched from other previous antipsychotic drugs to paliperidone.

Time frame:
Baseline and Week 26
Reported as:
Number · participants
Number of Participants Within Each Category of Patient Satisfaction Score
participantsPaliperidone ER: Lack of EfficacyPaliperidone ER: Lack of Tolerability, Compliance or Other
Very Good: Baseline (n= 507, 583)8 ± 32.7421 ± 34.67
Good: Baseline (n= 507, 583)74151
Reasonable: Baseline (n= 507, 583)256305
Moderate: Baseline (n= 507, 583)15897
Poor: Baseline (n= 507, 583)119
Very Good: Week 26 (n=492, 563)120156
Good: Week 26 (n=492, 563)173253
Reasonable: Week 26 (n=492, 563)11294
Moderate: Week 26 (n=492, 563)7050
Poor: Week 26 (n=492, 563)1710

Adverse events

Collected over 26 weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paliperidone ER: Lack of Efficacy—35/512 (6.8%)208/512 (40.6%)
Paliperidone ER: Lack of Tolerability, Compliance or Other—29/587 (4.9%)239/587 (40.7%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventPaliperidone ER: Lack of EfficacyPaliperidone ER: Lack of Tolerability, Compliance or Other
SchizophreniaPsychiatric disorders12/5127/587
Psychotic disorderPsychiatric disorders7/5123/587
Extrapyramidal disorderNervous system disorders0/5123/587
AgitationPsychiatric disorders2/5121/587
AggressionPsychiatric disorders1/5122/587
VomitingGastrointestinal disorders1/5122/587
InvestigationInvestigations1/5122/587
HallucinationPsychiatric disorders1/5121/587
Suicidal behaviourPsychiatric disorders1/5121/587
Abnormal behaviourPsychiatric disorders1/5120/587
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPaliperidone ER: Lack of EfficacyPaliperidone ER: Lack of Tolerability, Compliance or Other
InsomniaPsychiatric disorders50/51268/587
Extrapyramidal disorderNervous system disorders34/51221/587
HeadacheNervous system disorders23/51224/587
NauseaGastrointestinal disorders17/51223/587
DizzinessNervous system disorders16/51222/587
SomnolenceNervous system disorders9/51220/587
AkathisiaNervous system disorders13/51218/587
VomitingGastrointestinal disorders15/51216/587
RestlessnessPsychiatric disorders9/51213/587
TremorNervous system disorders9/51212/587

Baseline characteristics

Age, Customized
Age, Customized(Participants)Paliperidone ER: Lack of EfficacyPaliperidone ER: Lack of Tolerability, Compliance or OtherTotal
Less than (<) 25 years92 ± 11.63125 ± 11.90217
Greater than or equal to (>=) 25 to < 35 years153191344
>= 35 to < 45 years152152304
>= 45 to < 55 years8387170
>= 55 to < 65 years333467
>= 65 to < 75 years6713
Greater than 75 years112
Sex: Female, Male
Sex: Female, Male(Participants)Paliperidone ER: Lack of EfficacyPaliperidone ER: Lack of Tolerability, Compliance or OtherTotal
Female192268460
Male328329657
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Apr 2008 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 5 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2012
First posted
Aug 10, 2012
Start
Jun 2007
Primary completionActual
Apr 2008
CompletionActual
Apr 2009
Results first posted
Mar 26, 2014
Last update
May 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01662648
Responsible party
Sponsor
First posted
Aug 10, 2012
Start date
Jun 2007
Primary completion
Apr 2008
Completion
Apr 2009
Results posted
Mar 26, 2014
Last update
May 5, 2014

Study contacts

Janssen Pharmaceutica Clinical Trial
study director · Janssen Pharmaceutica

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion